	Application No.	Applicant(s)
Notice of Allowability	10/061,727	SIMS ET AL.
	Examiner	Art Unit
	Ruixiang Li	1646
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Applicants' amendment filed on 10/20/2005</u> .		
2. The allowed claim(s) is/are 1, 2, 5-7, 9-11, and 15, which will be issued as claims 1-9, respectively.		
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
	·	
Attachment(s)	_	
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	 Interview Summary Paper No./Mail Date 	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date	8), 7. 🛭 Examiner's Amendm	
4. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9.	

EXAMINER'S AMENDMENT/COMMENT

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or

additions be unacceptable to applicant, an amendment may be filed as provided by 37

CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no

later than the payment of the issue fee. Authorization for this examiner's amendment

was given in a telephone interview with Janis C. Henry on December 19, 2005.

Amendment to claims

In claim 5,

Replace sctions e) and f) by the following:

e) a full complement of a polynucleotide that hybridizes to nucleotides 1348-2061

of SEQ ID NO: 1 under conditions of moderate stringency in 50% formamide and

6XSSC, at 42°C with washing conditions of 60°C, 0.5XSSC, 0.1% SDS; wherein

the complement of the polynucleotide encodes a polypeptide that interacts with

an IL-1R signal transduction factor; and

f) a polynucleotide that encodes a polypeptide that is at least 95% identical to an

amino acid sequence consisting of amino acid residues selected from the group

consisting of residues 384-687 of SEQ ID NO: 2, residues 379-687 of SEQ ID NO: 2, and residues 449-687 of SEQ ID NO: 2, wherein the amino acid at 598 is Thr or Pro, and wherein the polypeptide interacts with an IL-1R signal transduction factor.

• delete section g).

In claim 10,

- in line 1, replace "a nucleic acid" by -a polynucleotide--.
- In line 2, delete "of claim 9", and insert --transformed with an expression vector comprising a polynucleotide of claim 5--.

Amendment to the Title

The title has been changed to more accurately reflect the claimed invention. The title now reads:

"DNA encoding IL-1 receptor accessary protein".

Conclusion

Claims 1, 2, 5-7, 9-11, and 15 are allowed. Claims 1, 2, 5-7, 9-11, and 15 are renumbered as claims 1-9, respectively.

Application/Control Number: 10/061,727

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the

Page 4

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony Caputa, can be reached on (571) 272-0829. The fax number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Rusciang L.

Ruixiang Li, Ph.D. Primary Examiner

December 19, 2005